Registry of Minimally Invasive Cancer Treatment Using Spectral Angio-CT Image Guidance (PreciseOnco)

Prospective Registry of Spectral Angio-CT-Guided Interventional Oncology Procedures in Routine Clinical Practice

This study collects data from patients undergoing minimally invasive, image-guided cancer treatments at participating hospitals in the Netherlands and France. All treatments are performed as standard clinical care and include procedures such as tumor ablation and catheter-based treatments of cancer in the liver, kidney, lung, and bone.

During these procedures, a spectral angio-CT system is used for image guidance. This advanced CT scanner automatically captures additional imaging information beyond what is used in routine clinical decision-making. The goal of this study is to investigate how this additional imaging information is associated with treatment outcomes, and how it can be used in the future to improve treatment planning, procedural guidance, and prediction of treatment results.

No experimental interventions are performed. Participation does not alter the treatment or follow-up patients receive. Data are collected from medical records and imaging systems and stored securely for analysis.

Study Overview

• Status: Not yet recruiting
• Conditions: Hepatocellular Carcinoma (HCC); Renal Cancer; Renal Cell Carcinoma (RCC); Lung Cancer (Diagnosis); Bone Tumors; Musculoskeletal Tumors; Lung Tumors; Bone Cancer Metastatic; Musculoskeletal Cancers; Bone Cancer Tumor; Kidney Tumors; Liver Cancer (Primary and Metastatic); Renal Cell Carcinoma (Kidney Cancer)

Detailed Description

Interventional oncology (IO) is an established component of cancer care, offering minimally invasive, image-guided treatments for solid tumors in organs such as the liver, kidney, lung, and musculoskeletal system. IO procedures include percutaneous techniques such as thermal ablation, as well as catheter-based approaches such as transarterial embolization, chemoembolization, and radioembolization. Compared to surgical approaches, these procedures are associated with lower morbidity and mortality, shorter hospital admissions, and lower costs.

Medical imaging plays a central role throughout the IO workflow, from diagnosis and treatment planning to procedural guidance and post-treatment assessment. One major advancement in this context is the integration of angiography and CT into a single angio-CT system, allowing seamless transitions between real-time fluoroscopy and high-resolution cross-sectional imaging during procedures.

The newest generation of angio-CT systems incorporates spectral CT technology, which enables energy-resolved imaging through dual-layer detector technology. This simultaneously acquires spectral data while providing conventional CT reconstructions, allowing standard workflow and image interpretation to remain unchanged while spectral information is available as additional imaging data. Spectral CT has the potential to enhance lesion detection and tissue characterization, reduce metal artifacts, and improve the accuracy of treatment evaluation compared with conventional CT.

All procedures are performed according to standard clinical care at the participating centers. Study participation does not influence clinical decision-making, treatment strategy, or follow-up. No experimental interventions are performed.

This is a prospective, observational, multicenter, international registry study coordinated by Leiden University Medical Center (LUMC). Participating centers include Leiden University Medical Center (LUMC, the Netherlands), Hospices Civils de Lyon (HCL, France), and Assistance Publique Hôpitaux de Paris (APHP, France). The study is part of the EU-funded PreciseOnco project, which aims to further integrate and optimize imaging and guidance technologies within clinical IO workflows.

• Study Type: Observational
• Enrollment (Estimated): 2000

Contacts and Locations

• Study Contact: Name: Emma C.M. Buijsman, MSc; Phone Number: +31 71 526 49 50; Email: e.c.m.buijsman@lumc.nl

Study Locations

• France
  • Auvergne-Rhône-Alpes
    • Lyon, Auvergne-Rhône-Alpes, France, 69002
      • Hospices Civils de Lyon - Hôpital Édouard Herriot
      • Contact: Prof. Dr. Laurent Milot; Email: laurent.milot@chu-lyon.fr
      • Principal Investigator: Prof. Dr. Laurent Milot
  • Île-de-France Region
    • Créteil, Île-de-France Region, France, 94000
      • Assistance Publique Hopitaux de Paris - Hôpital Henri Mondor
      • Contact: Prof Dr. Hicham Kobeiter; Email: hicham.kobeiter@aphp.fr
      • Principal Investigator: Prof Dr. Hicham Kobeiter
• Netherlands
  • South Holland
    • Leiden, South Holland, Netherlands, 2333 ZA
      • Leiden University Medical Center
      • Contact: Emma C.M. Buijsman, MSc; Phone Number: + 31 71 526 49 50; Email: e.c.m.buijsman@lumc.nl
      • Principal Investigator: Prof. Dr. Mark C. Burgmans
      • Sub-Investigator: Dr. Ir. Jouke Dijkstra

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Adult patients (18 years or older) with solid tumors undergoing clinically indicated minimally invasive cancer treatments at participating centers in the Netherlands and France. Eligible procedures include percutaneous techniques such as thermal ablation, and catheter-based approaches such as transarterial embolization, chemoembolization, and radioembolization, for tumors in organs including the liver, kidney, lung, and musculoskeletal system. The spectral angio-CT must be used as part of standard clinical care during the procedure. Patients who are incapacitated or have psychiatric disorders precluding informed consent are excluded.

Description

Inclusion Criteria:

• Age ≥ 18 years;
• Undergoing a clinically indicated IO procedure with a percutaneous or transarterial approach for solid tumors;
• Use of spectral angio-CT image guidance as part of standard care;
• Written confirmed consent.

Exclusion Criteria:

• Patients who are declared incapacitated;
• Patients suffering from psychic disorders that make a comprehensive judgement impossible.

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Local tumor control	Local tumor control at the treated site, assessed at 6 months, 1 year, 2 years, and 3 years after the procedure.	6 months, 1 year, 2 years, 3 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Overall survival	Time from the index procedure to death from any cause.	6 months, 1 year, 2 years, 3 years
Progression-free survival	Time from the index procedure to disease progression or death from any cause.	6 months, 1 year, 2 years, 3 years
Ablation margin and embolization completeness	Assessment of ablation margins and completeness of embolization using spectral CT imaging, compared to standard CT reconstructions.	At time of procedure
Incidence of periprocedural adverse events	Periprocedural complications and adverse events graded according to the Common Terminology Criteria for Adverse Events version 6 (CTCAEv6).	30 days after procedure
Procedure duration	Duration of the procedure to evaluate the workflow.	At time of procedure

Collaborators and Investigators

• Sponsor: Mark C Burgmans, MD PhD
• Collaborators: Assistance Publique - Hôpitaux de Paris; Hospices Civils de Lyon; Philips Electronics Nederland BV; European Commission; Quantum Surgical; Philips Medical Systems; Philips France Commercial; IGEA; Philips GmbH Innovate Technologies; Cardiovascular and Interventional Radiological Society of Europe; EIBIR - European Institute for biomedical imaging research; Klinikum der Universität zu Köln, Institut für Klinische Chemie

Publications and helpful links

Helpful Links

• Consortium website

Study record dates

Study Major Dates

• Study Start (Estimated): July 1, 2026
• Primary Completion (Estimated): December 31, 2030
• Study Completion (Estimated): December 31, 2030

Study Registration Dates

• First Submitted: May 28, 2026
• First Submitted That Met QC Criteria: June 3, 2026
• First Posted (Actual): June 9, 2026

Study Record Updates

• Last Update Posted (Actual): June 9, 2026
• Last Update Submitted That Met QC Criteria: June 3, 2026
• Last Verified: June 1, 2026

More Information

Terms related to this study

• Keywords: Thermal ablation; Registry; Cryoablation; Hepatocellular carcinoma; Renal cell carcinoma; Multicenter; Radiofrequency ablation; Microwave ablation; Liver metastases; Spectral CT; Transarterial chemoembolization; Progression-free survival; Interventional oncology; Tumor recurrence; Lung tumors; Image-guided therapy; Transarterial embolization; Transarterial radioembolization; Dual-layer detector CT; Angio-CT; Local tumor control; Musculoskeletal tumors
• Additional Relevant MeSH Terms: Urogenital Diseases; Bone Diseases; Musculoskeletal Diseases; Pathologic Processes; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Male Urogenital Diseases; Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Disease Attributes; Respiratory Tract Diseases; Neoplasms by Histologic Type; Digestive System Neoplasms; Digestive System Diseases; Lung Diseases; Liver Diseases; Neoplasms, Glandular and Epithelial; Adenocarcinoma; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplastic Processes; Urologic Neoplasms; Carcinoma; Pathological Conditions, Signs and Symptoms; Recurrence; Carcinoma, Hepatocellular; Lung Neoplasms; Disease; Neoplasm Metastasis; Liver Neoplasms; Carcinoma, Renal Cell; Kidney Neoplasms; Bone Neoplasms
• Other Study ID Numbers: 101252582

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No